Clinical Trials

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03633955 2026-03-05

REALIZE

LymphoidOther hematologic neoplasmPlasma cell

60 enrolled

Lymphoma, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell

NCT07297160 2026-03-04

CALySSEY

Phase 1 Not yet recruiting

88 enrolled

GenitourinaryLymphoidOther hematologic neoplasmPlasma cellSarcoma

Kidney Neoplasms, Lymphoma, Sarcoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT04155749 2026-02-11

Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma

Phase 1 Active not recruiting

40 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT05651932 2026-02-10

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

125 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03702725 2026-01-06

Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

14 enrolled 15 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05055063 2025-12-18

A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

30 enrolled

Neoplasms, Plasma Cell

NCT05182073 2025-12-12

FT576 in Subjects With Multiple Myeloma

31 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05065866 2025-12-04

Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy

LymphoidOther hematologic neoplasmPlasma cell

14 enrolled

Hodgkin Disease, Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Neoplasms, Plasma Cell

NCT06304636 2025-11-24

DC15-MM-01

Phase 1 Terminated

4 enrolled

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT06523699 2025-08-28

Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant

30 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06313502 2025-06-15

High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders

18 enrolled

Phase 1 Active not recruiting

Neoplasms, Plasma Cell

NCT04354246 2025-05-22

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

110 enrolled

GastrointestinalGynecologicHead & NeckPlasma cellThoracic

Squamous Cell Carcinoma of Head and Neck, Colonic Neoplasms, Lung Neoplasms, Multiple Myeloma, Ovarian Neoplasms, Neoplasms, Plasma Cell

NCT06892119 2025-03-27

Generic Plerixafor Efficacy of Autologous Hematopoietic Stem Cell Transplantation